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Abstract
AIM
To investigate the effect of a low-FODMAP diet on 
irritable bowel syndrome (IBS)-like symptoms in patients 
with inflammatory bowel disease (IBD).
METHODS
This was a randomised controlled open-label trial of 
patients with IBD in remission or with mild-to-moderate 
disease and coexisting IBS-like symptoms (Rome III) 
randomly assigned to a Low-FODMAP diet (LFD) or 
a normal diet (ND) for 6 wk between June 2012 and 
Submit a Manuscript: http://www.f6publishing.com
DOI: 10.3748/wjg.v23.i18.3356
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ORIGINAL ARTICLE
Low-FODMAP diet reduces irritable bowel symptoms in 
patients with inflammatory bowel disease
Randomized Controlled Trial
Natalia Pedersen, Dorit Vedel Ankersen, Maria Felding, Henrik Wachmann, Zsuzsanna Végh, Line Molzen, 
Johan Burisch, Jens Rikardt Andersen, Pia Munkholm
December 2013. Patients completed the IBS symptom 
severity system (IBS-SSS) and short IBD quality of 
life questionnaire (SIBDQ) at weeks 0 and 6. The 
primary end-point was response rates (at least 50-point 
reduction) in IBS-SSS at week 6 between groups; 
secondary end-point was the impact on quality of life. 
RESULTS
Eighty-nine patients, 67 (75%) women, median age 
40, range 20-70 years were randomised: 44 to LFD 
group and 45 to ND, from which 78 patients completed 
the study period and were included in the final analysis 
(37 LFD and 41 ND). There was a significantly larger 
proportion of responders in the LFD group (n  = 30, 
81%) than in the ND group (n  = 19, 46%); (OR = 
5.30; 95%CI: 1.81-15.55, P  < 0.01). At week 6, the 
LFD group showed a significantly lower median IBS-
SSS (median 115; inter-quartile range [IQR] 33-169) 
than ND group (median 170, IQR 91-288), P  = 0.02. 
Furthermore, the LFD group had a significantly greater 
increase in SIBDQ (median 60, IQR 51-65) than the ND 
group (median 50, IQR 39-60), P  < 0.01.
CONCLUSION
In a prospective study, a low-FODMAP diet reduced 
IBS-like symptoms and increased quality of life in 
patients with IBD in remission.
Key words: Inflammatory bowel disease; Web-based 
management; Irritable bowel syndrome; Low-FODMAP 
diet
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This is one of the first randomized controlled 
studies showing that low-FODMAP diet had ameliorative 
effect on irritable bowel syndrome (IBS)-like symp-
toms in a Danish inflammatory bowel disease (IBD) 
population in remission. The IBD quality of life were also 
improved on the same diet. Based on the results of this 
study, a low-FODMAP diet could be recommended for 
IBD patients in remission who are experiencing IBS-like 
symptoms. The diet requires guidance from a dietician 
for closely monitoring of the nutritional adequacy with 
dietary restriction.
Pedersen N, Ankersen DV, Felding M, Wachmann H, Végh 
Z, Molzen L, Burisch J, Andersen JR, Munkholm P. Low-
FODMAP diet reduces irritable bowel symptoms in patients 
with inflammatory bowel disease. World J Gastroenterol 2017; 
23(18): 3356-3366  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i18/3356.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i18.3356
INTRODUCTION
Inflammatory bowel diseases (IBD) are gastrointestinal 
disorders (GI) that include ulcerative colitis (UC) and 
Crohn’s disease (CD). The disease course of IBD is inter­
mittent, with periods of remission and activity[1]. Even 
though periods of remission enhance a patient’s well­
being, IBD patient will often still suffer from various 
functional symptoms which may affect their quality 
of life (QOL)[2]. Some IBD specific symptoms overlap 
symptoms similar to irritable bowel syndrome (IBS) 
such as bloating, abdominal pain, altered bowel 
habits (diarrhoea and/or constipation) and abdominal 
distension[3,4].
Approximately 40% of IBD patients may suffer 
from IBS­like symptoms[5,6]. It has been suggested 
that certain diets, such as one with increased dietary 
fiber or a lactose free diet[7,8], can influence IBS­
like symptoms. However, the benefits of these diets 
have not been verified. Recently, it has been shown 
that FODMAPs (Fermentable, Oligosaccharides, Dis­
accharides, Monosaccharides and Polyols), which are 
poorly absorbed in the small intestine and fermented 
by bacteria in the colon, can trigger symptoms 
such as bloating, abdominal pain, alter bowel habits 
(diarrhoea and/or constipation), and gas in sensitive 
individuals[9­11].
A diet containing high quantities of FODMAPs has 
been shown to increase GI symptoms[10,12], while a 
low­FODMAP diet (LFD) has been shown to ameliorate 
symptoms in IBS patients[13­17] and in IBD patients with 
IBS[18,19]. In a retrospective study from 2009, consisting 
of 72 IBD patients that had previously been on a LFD, 
Gearry et al[18], demonstrated significant (56% of 
patients) improvement of functional overall abdominal 
symptoms (pain, bloating, wind and diarrhoea) in 
patients on a LFD. In a recent prospective study of 
88 patients with IBD in remission with functional­like 
gastrointestinal symptoms (FGS) on a LFD, Prince et 
al[19] demonstrated a satisfactory relief of the FGS at 
week 5 when compared to week 0 (16% vs 78%, P 
< 0.001). Furthermore, a significant improvement 
of overall and individual symptoms such as stool 
consistency and frequency in this study has been 
observed. However, prospective randomized controlled 
data on the effects of a LFD on IBD patients are 
lacking. 
The aim of this study was to investigate whether a 
LFD would alter IBS­like symptoms and improve the 
quality of life among IBD patients.
MATERIALS AND METHODS
Study design
This was a randomized, open­label 6­wk study with 
the primary aim of evaluating the effect of a LFD on 
IBS­like symptoms in IBD patients with quiescent or 
mild­to­moderate activity where the primary end­
point was the number of patients achieving a 50­point 
reduction in IBS­SSS after six weeks, and secondarily, 
whether a LFD could improve QOL. All patients were 
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allocated to either a treatment group (LFD group) or a 
control group on a normal habitual diet (ND group). A 
person not involved in the study generated the random 
allocation sequence and numbered the envelopes.
Study subjects
Patients were recruited from a tertiary hospital in 
Copenhagen, Denmark between June 2012 and 
November 2013. 
The inclusion criteria were: (1) IBD patients 
in remission or with mild­to­moderate disease 
activity and coexisting IBS­like symptoms (Rome III 
criteria)[20,21] with a baseline IBS­SSS (IBS­symptom 
severity score) of at least 75 points[22]; and (2) IBD 
patients on maintenance therapy with 5­aminosalic 
acid (5­ASA), azathioprine (AZA) or biologicals or 
a combination of these, on a stable dose (no dose 
adjustments or additional medications were taken 
by patients in the 4 wk prior to entry in the study). 
Furthermore, no dose adjustments or additional 
medications were allowed during the study.
The exclusion criteria were: (1) IBD patients with 
moderate­to­severe relapse (SCCAI > 6, HBI > 12) at 
inclusion; (2) steroid treatment less than four weeks 
before inclusion; and (3) vegetarians or patients with 
coeliac disease, lactose intolerance (lactose blood and 
lactose gene test), allergies, or those on an alternative 
diet regimen.
Outcome measurements
IBS severity: Overall IBS­like symptoms were 
measured by the internationally validated IBS­
SSS[22]. The IBS­SSS score is structured as a five­
subscore visual analog scale (VAS), which can be 
self­administered or completed by a physician. It 
evaluates the intensity of IBS­like symptoms during 
the preceding 10 d with regards to the following 
subscores: abdominal pain intensity and duration, 
abdominal distension, stool frequency and consistency, 
and interference with life in general. Each of the 
five subscores generates a maximum score of 100 
points, which gives a maximum IBS­SSS total score 
of 500 points. A minimum of 50 points reduction in 
total IBS­SSS during the study was considered an 
improvement[22]. A minimum of 10 points reduction or 
more of each of the five subscores was also considered 
an improvement[13,15,18].
IBD activity: Disease activity of UC was measured by 
the Simple Clinical Colitis Index (SCCAI)[23]. A SCCAI 
score of ≤ 2 defines remission, > 2 mild-to-moderate, 
and > 6 severe disease activity.
Disease activity in CD was measured by the 
Harvey Bradshaw Index (HBI)[24]. A score < 5 defines 
remission, 5­7 mild activity, 8­12 moderate, and > 12 
severe disease activity.
Additionally, inflammatory biomarkers, faecal 
calprotectin (FC) and C­reactive protein (CRP), were 
used to measure disease activity at 0 and 6­wk of 
the study. Cut­off values of FC for remission was ≤ 
100 µg/g in UC[25,26] and ≤ 200 µg/g in CD[27­29]. A 
CRP cut­off value of ≤ 10 mg/L was used to define 
remission[28,30].
Additional measurements: Disease­related quality 
of life was assessed using the Short IBD Questionnaire 
(SIBDQ)[31] and the IBS Quality of Life (IBS­QOL)[32] 
questionnaire. A self­constructed food frequency 
questionnaire (FFQ)[33] was used to measure adherence 
to the diets. It contains lists of the most commonly 
consumed high­FODMAP foods adapted to a Danish 
population, Supplementary Table 1 (Supplemental 
Digital Content 1). Patients’ FFQ was used to calculate 
their FODMAP intake in gram per day (g/d). 
Dietary procedure
At baseline, all patients underwent a 30­min, appoint­
ment for dietary assessment (including nutritional 
status) with nutritionists and a dietary intake was 
obtained from all patients using the FFQ. Thereafter, 
patients in the intervention group were given an 
individual one­hour counseling session about the LFD. 
Detailed information regarding the LFD was provided, 
including handouts with recipes, tips, and meal plans. 
Patients in the ND group were requested to follow an 
unchanged habitual diet during the 6­wk. At the end 
of the study all LFD patients had a 30­min follow up 
counseling session with the nutritionists, in which they 
were reintroduced to the high­FODMAP foods that had 
been restricted or forbidden during the 6­wk study 
period. 
Web-based application: www.ibs.constant-care.dk
The web­based application www.ibs.constant­care.
dk[16,34,35] was specifically designed for IBS and IBD 
patients in order to facilitate self­management with 
the registration of IBS­like symptoms and to monitor 
the severity of their disease and QOL. At baseline, all 
patients underwent a medical history assessment, 
including prior treatment, and were introduced (30­min 
session) to the web­based questionnaires (IBS­
SSS, IBS­QOL) and non­web­based questionnaires 
(IBDQ, SCCAI, HBI), all completed by participants at 
0 and 6­wk. Detailed information on the application 
and patient registration are shown in Supplementary 
Figures 1 (Supplemental Digital Content 2) and 2 
(Supplemental Digital Content 3).
Sample size determination
Sample size was estimated to be 80 patients in total: 
40 patients in the ND group and 40 patients in the 
intervention group. The assumed standard deviation 
(SD) of 6­wk IBS­SSS scores and the smallest relevant 
clinical difference between groups were 80 and 50, 
respectively[21,36]. The standard deviation for IBS­SSS 
was based on a previous study[34] α and β were set to 
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each treatment group, testing for a decrease in IBS­
SSS score within each treatment group. The Mann­
Whitney U test was performed to compare treatment 
groups with respect to a decrease in IBS­SSS score. 
A P­value of < 0.05 was considered statistically sig­
nificant. Corelation analysis between outcomes was 
performed using the non­parametric Spearman’s 
rank correlation.
Multivariate logistic regression analysis was used 
to evaluate the impact on change/response of the 
total IBS­SSS and IBS­SSS subscores of the following 
factors/covariates: baseline IBS­SSS, diet, age ≤ 40 
years, BMI, diagnosis, gender, IBD duration ≤ 5 years, 
smoking, prior surgery, IBD maintenance therapy 
(5­ASA, thiopurines and biologicals) and disease 
activity.
All data were processed in SPSS software Version 
20 for Windows (SPSS Inc., Chicago, IL) and SAS 
software version 9.3 (SAS Institute Inc. Care. NC, 
Unites States).
ethical considerations
The Ethical Committee, Denmark (protocol number 
H­2­2012­05/38987) approved the study. All patients 
included in this study signed an informed consent 
document. 
RESULTS
Patients flow and baseline characteristics
A total of 100 IBD patients with coexisting IBS­like 
symptoms were screened for their eligibility in the 
study, of which 89 patients [61 (69%) with UC and 
28 (31%) with CD] were randomly assigned to either 
the LFD (n = 44) or ND (n = 45) groups. Eleven 
patients (12%) discontinued the study one week after 
enrolment, seven (8%) patients in the LFD and four 
(4%) in the ND group, due to difficulty with the diet in 
the LFD group and a lack of compliance with the web 
program in the ND group. The final group comprised 
78 patients (LFD, n = 37 vs ND, n = 41) and were 
included in a PP analysis. Additionally, all 89 patients 
were included in an ITT analysis of primary outcome.
There were not significant differences in demo­
graphic and disease characteristics data between 
groups apart from there being more smokers and prior 
surgery observed in the LFD group. The flow of the 
patients in the study is shown in Figure 1. Baseline 
characteristics of patients by treatment group are 
shown in Table 1. 
IBS-like symptoms (IBS-SSS)
A total of 30 (81%) patients were responders in the 
LFD group as opposed to 19 (46%) in the ND group, 
P < 0.01. The response rates in IBS­SSS subscores 
among IBD patients are illustrated in Figure 2. At 6­wk, 
a significantly lower IBS­SSS score was observed in 
the LFD group (median IBS­SSS 115, IQR 33­169) 
5 % and 20 %, respectively.
Statistical analysis
Descriptive statistics were performed, including fre­
quency distributions for categorical data and means, 
medians/interquartile ranges (IQR) for continuous 
variables. Per protocol (PP) and intention­to­treat 
(ITT) analyses were performed on primary end­point. 
Inflammatory biomarkers (CRP, FC) were analyzed as 
geometric means and coefficient of variations (CVs) 
were added. The Wilcoxon signed­rank test was used 
for comparing paired samples (0­wk vs 6­wk) within 
Table 1  Baseline characteristics of the patients
Low-FODMAP 
diet, n  = 44
Normal diet,
 n  = 45
P value
Male/Female 12 (27)/32 (73) 10 (23)/35 (77) 0.64
Age, median (range) 40 (20-70) 41 (24-69) 0.55
Body mass index, median 
(range) 
25 (18-39) 24 (18-52) 0.44
Smoking 0.01
   Current 8 (18) 2 (4)
   Former 19 (43) 12 (28)
   Never 17 (39) 30 (68)
IBD diagnosis type 0.93
   Ulcerative colitis (UC) 30 (68) 31 (69)
   Crohn’s disease (CD) 14 (32) 14 (31)
UC extent 0.34
   E1, proctitis   7 (23) 11 (36)
   E2, left side 15 (50) 10 (32)
   E3, extensive   8 (27) 10 (32)
CD location 0.51
   L1, small bowel   4 (29) 3 (21)
   L2, colonic   4 (29) 7 (50)
   L3, ilea-colonic   6 (42) 4 (29)
CD behavior 0.13
   B1, inflammatory   6 (43) 11 (79)
   B2, stricturing   6 (43)   2 (14)
   B3, penetrating   2 (14) 1 (7)
IBD duration, median 
(range)
  7 (1-40)   5 (1-39) 0.41
IBD disease activity (yes)   6 (14%)   7 (16%) 0.52
UC disease activity (SCCAI) 3 (1-4) 2 (1-4) 0.75
CD disease activity (HBI) 7 (3-8)   5 (4-11) 0.61
IBS severity (IBS-SSS)     210 (190-270)     245 (180-320) 0.40
IBS-quality of life   73 (19-99)   77 (30-98) 0.25
Short-IBD-quality of life 
(SIBDQ)
  47 (42-55)   50 (40-57) 0.88
C-reactive protein (mg/L), 
median (range)
  2 (2-35)   2 (2-52) 0.32
Faecal calprotectin (µg/L), 
median (range)
50 (2-1259) 39 (2-1600) 0.28
FODMAPs (g/d), median 
(range)
24 (9-81) 26 (4-58) 0.53
Surgery prior study 11 (25) 2 (4) 0.01
Medication: Yes/No 34/10 38/7 0.41
5-ASA/Sulphasalazine 23 (52) 25 (55)
Azathioprine (AZA)/
Methotrexate
4 (9) 7 (15)/1 (2)
Biologicals ± AZA   5 (11) 4 (9)
Data are expressed as n (%), median (IQR: Interquartile range). IBD: 
Inflammatory bowel disease; IBS: Irritable bowel disease; SSS: Symptom 
severity scale; SCCAI: Simple clinical colitis index; HBI: Harvey Bradshaw 
index.
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as compared to the ND group (median IBS­SSS 170, 
IQR 91­288), P = 0.02 (Table 2, Figure 3). Adjusted 
for baseline characteristics, logistic regression analysis 
identified IBS-SSS LFD/ND treatment Odds ratio (OR) 
(OR = 5.30, 95%CI: 1.81­15.55, P < 0.01) as clearly 
associated with the overall IBS­SSS response (Figure 2). 
The analysis of IBS­SSS subscores showed that patients 
on a LFD had a significantly greater reduction in pain 
duration as compared to those on a ND (OR = 2.97, 
95%CI: 1.12­7.89, P = 0.03) as well as a trend towards 
an improvement in stool frequency and consistency (OR 
= 2.43, 95%CI: 0.97­6.12, P = 0.06) (Figure 2). IBD 
duration ≤ 5 years was associated with pain intensity 
reduction (OR = 0.23, 95%CI: 0.08­0.65, P < 0.01) 
and less interference with life in general (OR = 0.33, 
95%CI: 0.12­0.88, P = 0.03), Supplementary Table 2 
(Supplemental Digital Content 4).
The subgroup analysis of IBS­SSS according to 
disease activity (Table 3) showed that IBD patients 
in remission had a significantly better response on 
LFD (median IBS­SSS 105, IQR 26­167) than on ND 
(median IBS­SSS 175, IQR 77­298), P < 0.01. No 
difference in IBS­SSS was observed in IBD patients 
with mild­to­moderate disease activity, LFD (median 
IBS­SSS 169, IQR 105­332) vs ND (median IBS­SSS 
140, IQR 96­211, P = 0.53). Furthermore, CD patients 
on LFD had a significantly greater IBS-SSS reduction 
(median IBS­SSS 58, IQR 18­173) than those on ND 
(median IBS­SSS 220, IQR 57­357), P = 0.02, while 
no impact of diet in UC was seen, LFD (median IBS­
SSS 120, IQR 36­170) vs ND (median IBS­SSS 141, 
IQR 52­263, P = 0.37) (Table 3). 
IBS­SSS response according to disease activity 
measured by FC (total n = 73) (Table 3) showed that 
patients experiencing FC­remission (< 100 µg/g in 
UC, < 200 µg/g in CD) n = 53/73 (73%) had a better 
response to LFD (median IBS­SSS 60, IQR 29­169) 
than to a ND (median IBS­SSS 174, IQR 66­298), P = 
0.06. In those with FC­activity (FC > 100 µg/g in UC 
and > 200 µg/g in CD), n = 20/73 (27%) both LFD 
and ND patients responded significantly at 6-wk, with 
no significant difference observed between groups LFD 
(median IBS­SSS 150, IQR 95­198) vs ND (median 
IBS­SSS 170, IQR 103­291), P = 0.49.
IBS­SSS response according to disease activity 
measured by CRP (Table 3) showed that patients 
experiencing CRP­remission (< 10 mg/L) (96%), had a 
significant response in both the LFD and ND groups at 
Figure 1  Enrollment and progress of patients in the study. IBD: Inflammatory bowel disease; ND: Normal diet; LFD: Low-FODMAP diet.
IBD patients assessed for
eligibility
n  = 100
Randomised, n  = 89
Excluded, n  = 11
Not meeting inclusion criteria
LFD, n  = 44
LFD, n  = 7
LFD, n  = 37 ND, n  = 41
ND, n  = 4
ND, n  = 45
Enrollment
Allocation
Discontinued
Not analysed
Completed
Analysed
n  = 78
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6­wk, with a larger response in the LFD group (median 
IBS­SSS 114, IQR 30­169) vs ND group (median IBS­
SSS 176, IQR 78­288), P < 0.01.
The IBS­SSS response rates in different subgroups 
of IBD patients on the LFD and ND are shown in 
Supplementary Table 3 (Supplemental Digital Content 
5). No significant difference in response rates between 
UC 36 (66%) vs CD patients 13 (57%), P = 0.31 was 
observed.
As with PPT analysis, ITT responder analysis of all 
89 patients showed a statistically significant increase 
of the response rates of IBS­SSS in LFD as compared 
to that of ND (OR = 3.34, 95%CI: 1.28­8.30, P = 0.01).
Disease activity in UC and CD
In total, 65 (83%) patients were in remission and 13 
(17%) had mild­to­moderate activity upon entry to the 
study (Table 1). A statistically significant reduction in 
SCCAI change was observed for the LFD in UC patients 
(median 1, IQR 0­3) as compared to the ND (median 
2, IQR 1­4), P = 0.02 [Table 2, Supplementary Figure 
3, (Supplemental Digital Content 6)]. In patients with 
CD no significant reduction of HBI was observed in 
those on a LFD (median 3, IQR 1­5) vs ND (median 6, 
IQR 3­9), P = 0.09 (Table 2). A significant correlation 
between HBI and IBS­SSS improvement was found 
(rho = 0.4, P = 0.005). Furthermore, among UC 
patients a significant correlation between reduction of 
Figure 2  Logistic regression analysis of the total irritable bowel syndrome-severity score system response and its subscores for the normal diet and low 
FODMAP diet groups at 6-wk. IBS: Irritable bowel syndrome; SSS: Symptom severity score; ND: Normal diet; LFD: Low-FODMAP diet; N: Number; L95CI: Lower 
95% confidence interval; U95CI: Upper 95% confidence interval.
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Figure 3  Box plot of irritable bowel syndrome-severity score system 
crude data in means ± SD, medians (range) for the normal diet and low 
FODMAP diet groups at 0 vs 6-wk. IBS: Irritable bowel syndrome; SSS: 
Symptom severity score; ND: Normal diet; LFD: Low-FODMAP diet.
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SCCAI and improvement in IBDQ (r = ­0.53, P < 0.001) 
was observed. However, in CD patients the correlation 
between HBI and IBDQ was not significant (rho = 0.38, 
P = 0.09). 
Quality of life 
At wk­6, a statistically significant improvement in 
SIBDQ was observed in those on a LFD (median 60, 
IQR 51­65) when compared to those on a ND (median 
50, IQR 39­60), P < 0.01 (Table 2, Figure 4). IBS­QOL 
did not improve significantly in either the LFD (median 
78, IQR 51­65) or ND (median 81 IQR 26­99) groups, 
P = 0.09 (Table 2).
C-reactive protein
Seventy­five (96%) and 74 (95%) patients had 
C­reactive protein (CRP) levels lover than 10 mg/L at 
week 0 and 6, respectively. There was a significant 
difference in geometric mean CRP in the ND group 
at 6­wk (2.6; 95%CI: 2.1­3.3) as compared to 0­wk 
(2.2; 95%CI: 1.8­2.5), P = 0.04. While no difference 
in mean CRP in the LFD group was observed at 6­wk 
(2.8; 95%CI: 2.2­3.5) compared 0­wk (2.7; 95%CI: 
2.2­3.2), P = 0.57. Likewise, no significant difference 
between the LFD and ND groups with regards to CRP 
Table 2  Results of main outcomes in inflammatory bowel 
disease patients on low-FODMAP diet
Number Week 0 Week 6 P  value
Irritable Bowel Syndrome-Symptom Severity System (IBS-SSS) 
   Low-FODMAP 37 210 (190-270) 115 (33-169) < 0.001
   Normal diet 41 245 (180-320) 170 (91-288) < 0.001
0.021
Simple Clinical Colitis Index (SCCAI)
   Low-FODMAP  24 3 (1-4) 1 (0-3)    0.04
   Normal diet 29 2 (1-4) 2 (1-4)    0.98
0.021
Harvey and Bradshaw Index (HBI)
   Low-FODMAP    9 7 (3-8) 3 (1-5)    0.05
   Normal diet 12   5 (4-11) 6 (3-9)    0.25
0.091
Irritable Bowel Syndrome Quality of Life (IBS-QOL)
   Low-FODMAP 36 73 (19-99) 78 (18-99) < 0.01
   Normal diet 41 77 (30-98) 81 (26-99)    0.30
0.091
Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
   Low-FODMAP 34 47 (42-55) 60 (51-65) < 0.01
   Normal diet 40 50 (40-57) 50 (39-60)    0.54
< 0.011
1P: Mann-Whitney U test comparison of change in outcomes between 
treatment groups at 6-wk. All data are presented as median (IQR: 
Interquartile range). P: Wilcoxon signed rank test, comparison of paired 
samples 0 vs 6-wk for all subjects; All IBS-QOL results on 0-100 scale (0 
worst, 100 best).
Table 3  Results of irritable bowel syndrome-symptom 
severity system response in subgroups of inflammatory bowel 
disease patients on low FODMAP
Number Week 0 Week 6 P  value
Ulcerative colitis (UC)
   UC 55 (71) 220 (190-300) 124 (40-198) < 0.01
   LFD 26 (47) 225 (187-260) 120 (36-170) < 0.01
   ND 29 (53) 220 (185-315) 141 (52-263) < 0.01
0.371
Crohn’s disease (CD)
   CD 23 (29) 245 (170-320) 170 (56-294) < 0.01
   LFD 11 (48) 210 (160-320)   58 (18-173)    0.02
   ND 12 (52) 250 (172-382) 220 (57-357)    0.54
0.021
UC vs CD, P = 0.241
IBD-Remission by SCCAI/HBI
   Remission 65 (83) 230 (175-305) 140 (39-212) < 0.01
   LFD 31 (48) 220 (170-250) 105 (26-167) < 0.01
   ND 34 (52) 242 (177-322) 175 (77-298) < 0.01
< 0.011
IBD Mild-to-Moderate Activity by SCCAI/HBI
   Activity 13 (17) 210 (200-350)   140 (103-252)    0.53
   LFD   6 (46) 210 (194-391)   169 (105-332)    0.17
   ND   7 (54) 260 (200-330) 140 (96-211)    0.06
0.531
Remission vs Activity, P < 0.011
FC-remission (≤ 100 µg/g UC, ≤ 200 µg/g CD), n = 53
   Remission 53 (73) 220 (179-305) 113 (34-225) < 0.01
   LFD 25 (47) 220 (174-305)   60 (29-169) < 0.01
   ND 28 (53) 230 (180-307) 174 (66-298) < 0.01
0.061
FC-activity (> 100 µg/g UC; > 200 µg/g CD), n = 20
   Activity 20 (27) 250 (204-330)   160 (110-211) < 0.01
   LFD 11 (55) 210 (200-250) 157 (95-198)    0.04
   ND   9 (45) 320 (230-360)   170 (103-291)    0.03
0.501
FC-Remission vs FC-Activity, P = 0.291
CRP-remission (< 10 mg/L), n = 75
   Remission 75 (96) 230 (180-320) 140 (50-211) < 0.01
   LFD 35 (47) 210 (187-260) 114 (30-169) < 0.01
   ND 40 (53) 248 (180-320) 176 (78-288) < 0.01
< 0.011
CD, prior surgery (bowel/ileo-coecal resections), n = 13/23 (57%)
   LFD 11 225 (178-302) 10 (32-223) < 0.01
   ND   2 - -
1P: Mann-Whitney U test comparison of change in outcomes between 
treatment groups at 6-wk. All data are presented as median (IQR: 
Interquartile range), n (%) (- only 2 cases). P: Wilcoxon signed rank test, 
comparison of paired samples within each treatment group. IBS: Irritable 
bowel syndrome; SSS: Severity score system; IBD: Inflammatory bowel 
disease; LFD: Low FODMAP diet; ND: Normal Diet.
70
60
50
40
30
20
0                                      6
                 t/wk
ND
LFD
SI
BD
Q
P  < 0.001
Figure 4  Box plot of short inflammatory bowel disease questionnaire 
crude data in means ± SD, medians (range) for the normal diet and low 
FODMAP groups at 0 vs 6-wk. SIBDQ: Short inflammatory bowel disease 
quality of life; ND: Normal diet; LFD: Low-FODMAP diet.
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change at the end of the study was observed, P = 0.23, 
Supplementary Table 4 (Supplemental Digital Content 7). 
FC
Seventy­three (94%) patients collected FC at the 
baseline. Of these, 53 (73%) at baseline and 51 
(69%) at 6­wk had FC levels < 100 µg/g among UC 
patients or < 200 µg/g among CD patients. There 
was no significant difference in geometric mean FC 
in either the LFD 6­wk (mean 53; 95%CI: 30­93) 
vs 0­wk (mean 65; 95%CI: 37­113), P = 0.75 or 
ND 6­wk (mean 46; 95%CI: 27­81) vs ND 0­wk 
(mean 44; 95%CI: 23­83) vs, P = 0.46. Likewise, 
no significant difference between the LFD and ND 
groups with regards to FC change at the end of the 
study was observed, P = 0.41, Supplementary Table 4 
(Supplemental Digital Content 7).
Adherence to the diets
The quantity of FODMAPs in g/d was determined for 
all 78 patients (100%) at 0­wk and in 73 patients 
(94%) at 6-wk. At baseline, there was no significant 
difference in FODMAP g/d ingested by ND (median 26, 
range 4­58) vs LFD patients (median 24, range 9­81), 
P = 0.53. At the end of the study, the LFD patients had 
a significantly lower FODMAP g/d intake (median 2, 
range 0­49) than the ND patients (median 24, range 
2­68), P = 0.04, Supplementary Table 5 (Supplemental 
Digital Content 8).
DISCUSSION
To our knowledge this study is the first prospective, 
randomized study conducted in a Danish population 
investigating the impact of a LFD among IBD patients 
in remission or with mild­to­moderate disease activity 
with IBS­like symptoms. This study showed a greater 
response rate for patients on a LFD and a substantial 
reduction in overall IBS­like symptoms measured by 
IBS­SSS in patients on a LFD compared to a ND by the 
end of the study (6­wk). 
Subgroup analysis of this study in IBS­SSS res­
ponse indicates that LFD is beneficial for IBD patients 
in remission. Since only six IBD patients had activity 
in their disease while being on a LFD in this study the 
question of the efficacious role of a LFD in patients 
with mild­to­moderate­activity remains inconclusive 
and further studies are needed. 
Subgroup analysis of IBS­SSS showed that CD 
patients benefited most from the LFD, many of 
whom had a history of bowel surgery. UC patients, 
on the other hand, did not show any considerable 
improvement on IBS­SSS even though they were 
greater in number than CD patients. UC treated with 
a LFD did, however, show improvement in the disease 
activity (SCCAI). Furthermore, a strong correlation 
between SCCAI and IBDQ is shown in this study and 
demonstrates that UC patients are likely to benefit 
from a LFD.
The results of this study are consistent with the 
retrospective results of an Australian study with 
regards to overall IBS­like symptoms and separate 
IBS­SSS subscores[18]. The authors demonstrated a 
considerable reduction of diarrhoea (58% for UC and 
46% for CD). A newly published prospective study 
from England, based on 88 IBD patients, also supports 
the effect of a LFD in treating IBS­like symptoms in 
IBD patients[19]. This study found a substantial relief in 
functional­like gastrointestinal symptoms, stool type 
and frequency; however, due to the design they were 
not able to form conclusions as to the effect of a LFD 
on disease activity. 
A validated IBS­SSS questionnaire was used 
for assessment of severity of IBS­like symptoms 
in this study. However, it seems that the IBS­SSS 
questionnaire might be suited to monitoring IBS­
like symptoms in CD than in UC since the subgroup 
analysis only showed a response among CD patients. 
One explanation for this could be that two-fifths of the 
questions on the IBS­SSS score address abdominal 
pain and this is the main symptom in CD, while only 
one­fifths of questions of the IBS­SSS concerns 
stool habits and these are especially relevant in UC. 
Perhaps the Australian method, using a self­developed 
GI rating VAS questionnaire on specific and general 
symptoms would be more accurate for measuring IBS­
like symptoms in IBD patients[9,12,13,17].
IBS­like symptoms could be triggered by 
FODMAPS, which are osmotic molecules that can cause 
diarrhea, flatulence, and bloating (gas production) that 
may lead to abdominal pain[10]. Data from this study 
suggest that a LFD may affect disease activity indices 
(that measure functional symptoms) by altering IBS­
like symptoms such as abdominal pain and stool 
consistency/frequency, overlapping symptoms included 
in the HBI and SCCAI activity indices[37­40]. Although 
no mucosal endoscopic evaluation in this study was 
performed, inflammatory biomarkers (CRP, FC) were 
used to assess disease activity in the study. Results 
from this study did not show that the LFD affects 
inflammatory biomarkers (CRP, FC), suggesting that 
the dietary interventions did not improve inflammation 
either.
Additionally, the effect of the LFD on the micro­
biome and metabolites will also be important when 
evaluating the nutritional adequacy of the LFD since 
many IBD patients have a dysbiotic microbiota 
with for instance, a decreased Faecalibacterium 
prausnitzii[41]. Halmos et al[42] have demonstrated that 
a LFD can decrease the abundance of bifidobacteria 
and Faecalibacterium prausnitzii in IBS patients. The 
nutritional adequacy, including weight gain or loss 
while on the restrictive LFD, needs to be examined 
in future studies since both parameters are essential 
for many IBD patients. Based on these findings the 
authors recommend a LFD for short­term use only in 
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managing IBS symptoms, after which, high FODMAP 
foods should be reintroduced. As such, reintroduction 
of FODMAPs after a 6­wk LFD likewise be encouraged 
among IBD patients due to a lack of evidence 
regarding the long­term effects and consequences of 
the diet[9,43].
Besides improvements in IBS­like symptoms, this 
study also demonstrated a substantial improvement of 
the QOL in patients on a LFD for six weeks, which can 
partly be explained by the ranked correlations between 
SIBDQ and IBS­SSS/SCCAI. In a retrospective long­
term follow­up study of 43 IBD patients on a LFD, 
Maagaard et al[44] demonstrated an improvement in 
their Copenhagen IBS disease course type from a 
more chronic intermittent course to a milder, indolent 
one. 
The aim of using a web­based approach for 
monitoring IBS­like symptoms is to involve patients 
in the self­management of their disease[34]. The web­
based symptom monitoring approach in this study is 
a kind of diary in which the IBS­like symptoms and 
data on IBS quality of life were registered at least at 
the baseline and the end of the study. This approach 
may have had an impact on IBS­like symptoms 
independent of dietary intervention, as previously 
reported by Pedersen et al[16]. Nevertheless, web 
monitoring was used in both groups of patients, and 
thus one can assume that the differences observed 
between the LFD and ND groups are attributable to 
their specific diets. 
The strength of this study is that it is the first 
prospective, randomized study performed in a 
European population. The sample size is relatively 
large, and the results are significant, based on relevant 
questionnaires. The study evaluates subjective 
clinical symptoms, QOL and objective markers of 
inflammation. 
A major limitation of this study is that the groups 
were not blinded with regard to their diets and 
therefore it was possible for the ND patients to search 
for information about the topic on the internet and 
subsequently change their eating habits accordingly. 
While a blinded diet is possible in dietary trials, as 
shown by Halmos et al[15], these interventions are 
difficult to carry out as they require special facilities, 
are time consuming, expensive and do not represent 
standard clinical practice. Although the diet in our 
study was not blinded, the results of FFQ (LFD group 
consumed less FODMAPS compared to the ND), 
confirm that patients had an optimal adherence to the 
diet, obtained by a tight diet control by nutritionists 
during the study period.
A LFD may be difficult to follow without guidance 
from a dietician to help individualize and optimize the 
diet in order to obtain a greater symptom response[45]. 
In addition, guidance from a dietician ensures better 
nutritional adequacy during the use of the restrictive 
LFD.
Finally, the heterogeneity of IBD patients makes it 
difficult to distinguish IBS-like symptoms from IBD and 
considering the significant placebo effects (diet and 
web) in this study, both make it difficult to draw any 
firm conclusions[40].
In conclusion, this study supports the claim that 
LFD intervention has a beneficial effect among IBD 
patients in remission with IBS­like symptoms, as the 
results from this study show amelioration of symptoms 
and improvement in the quality of life. Based on these 
results a dietician­assisted LFD could be recommended 
in the short­term for IBD patients in remission who are 
experiencing IBS­like symptoms.
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COMMENTS
Background
Diet low in FODMAPs has shown to be beneficial in reducing symptoms in 
patients with irritable bowel syndrome (IBS). Furthermore, it has as well been 
shown to ameliorate IBS-like symptoms in patients suffering from inflammatory 
bowel disease (IBD) in one retrospective and one prospective study, however, 
no randomized controlled trail (RCT) has ever substantiated the beneficial effect 
of the diet for IBD.  
Research frontiers
The study demonstrates the effect of the low FODMAP diet in IBD patients in 
remission with IBS-like symptoms in a RCT. 
Innovations and breakthroughs
This is the first RCT investigating the effect of the low FODMAP diet on IBD 
patients in remission with co-existing IBS symptoms. The study supports the 
current evidence that the diet ameliorates IBS symptoms and improves quality 
of life for IBD patients. 
Applications
Low-FODMAP may be recommended for patients with IBD in remission and 
co-existing IBS-like symptoms, however, further studies are need in order to 
specify how this diet regime should be implemented with focus on time on the 
diet, gut microbiota and nutritional status. 
Terminology
Fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols 
(FODMAPs) are poorly absorbed and rapidly fermentable carbohydrates and 
sugar alcohols triggering abdominal symptoms. IBS-like symptoms in IBD 
patients are presented by abdominal symptoms such as abdominal distension, 
bloating, abdominal pain and diarrhoea. IBS-severity scoring system (IBS-
SSS) is an international validated score used for the measuring of the severity 
of the IBS symptoms. www.ibs.constant-care.dk is a web-based database for 
monitoring of IBS symptoms and quality of life constructed to be used by both 
IBS patients and IBD patients. 
Peer-review
The author showed in their study that low-FODMAP diet reduces irritable bowel 
symptoms in patients with inflammatory bowel disease in remission while the 
question of the efficacious role of LFD in patients with mild-to-moderate-activity 
remains inconclusive. Further studies are required to demonstrate possible 
changes in inflammatory cytokines, microbiota profile, and SCFAs, which may 
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have consequences for gut health with the low FODMAP diet. In addition to 
appropriate FODMAP manipulation, a dietician will assess and closely monitor 
nutritional adequacy with dietary restriction and manage as appropriate, 
including patients in whom nutrient absorption is impaired or dietary intake is 
altered.
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